Global Rare Kidney Diseases Market Size and Forecast 2023-2032|Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca plc, GlaxoSmithKline plc,

The Rare Kidney Diseases Global Market Report 2023, provides comprehensive information on the rare kidney diseases market across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.

Learn More On The Rare Kidney Diseases Market’s Growth:

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

The global rare kidney diseases market size is expected to grow from $2.27 billion in 2022 to $2.52 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of rare kidney diseases market is expected to reach $3.69 billion in 2027 at a CAGR of 10.0%.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample_request?id=11908&type=smp

Product innovation is a key trend gaining popularity in the rare kidney disease market. Major market players are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in September 2022, STADA Arzneimittel AG, a Germany-based company operating in generics, specialty pharma, and non-prescription consumer healthcare products, introduced Kinpeygo (budesonide), the first medicine authorized in the EU for treating rare kidney disease for treating a rare kidney disease immunoglobulin A nephropathy (IgAN). The modified-release budesonide capsules are the first and only approved treatment in the EU for primary IgAN, a rare, progressive autoimmune kidney disease with a high unmet need, with more than 25%-30% of patients eventually developing terminal kidney insufficiency requiring dialysis or kidney transplantation.

The rare kidney diseases market is segmented:

1) By Target Indication: IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications

2) By Type of Molecule: Small Molecules, Biologics

3) By Route of administration: Oral, Intravenous, Subcutaneous, Other Routes of Administration

North America was the largest region in the rare kidney diseases market in 2022.

The table of contents in TBRC’s rare kidney diseases market report includes:

1. Executive Summary

2. Rare Kidney Diseases Market Characteristics

3. Rare Kidney Diseases Market Trends And Strategies

4. Rare Kidney Diseases Market – Macro Economic Scenario

5. Rare Kidney Diseases Market Segmentation

.

.

.

26. South America Rare Kidney Diseases Market

27. Brazil Rare Kidney Diseases Market

28. Middle East Rare Kidney Diseases Market

29. Africa Rare Kidney Diseases Market

30. Rare Kidney Diseases Market Competitive Landscape And Company Profiles

 Top Major Players: